You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDiphenoxylate
Accession NumberDB01081  (APRD00366)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.
Structure
Thumb
Synonyms
1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester
2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile
4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile
Difenossilato
Difenoxilato
Diphenoxylatum
Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate
Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate
External Identifiers
  • DEA No. 9170
  • R-1132
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Diphenoxylate HCl and Atropine SulfateStat Rx USA
Diphenoxylate Hydrochloride and Atropine SulfateRoxane Laboratories, Inc
Direct RxDIRECT RX
LomotilG.D. Searle LLC Division of Pfizer Inc
Salts
Name/CASStructureProperties
Diphenoxylate Hydrochloride
Thumb
  • InChI Key: SHTAFWKOISOCBI-UHFFFAOYSA-N
  • Monoisotopic Mass: 488.223056017
  • Average Mass: 489.048
DBSALT000809
Categories
UNII73312P173G
CAS number915-30-0
WeightAverage: 452.5873
Monoisotopic: 452.246378278
Chemical FormulaC30H32N2O2
InChI KeyInChIKey=HYPPXZBJBPSRLK-UHFFFAOYSA-N
InChI
InChI=1S/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3
IUPAC Name
ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate
SMILES
CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylacetonitriles. These are cyclic aromatic compounds containing a diphenylacetonitrile moiety, which consists of a diphenylmethane linked to and acetonitrile to form 2,2-diphenylacetonitrile.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylacetonitriles
Direct ParentDiphenylacetonitriles
Alternative Parents
Substituents
  • Diphenylacetonitrile
  • Diphenylmethane
  • Phenylpiperidine
  • Phenylpropylamine
  • Phenylacetate
  • Piperidinecarboxylic acid
  • Benzyl-cyanide
  • Aralkylamine
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor as adjunctive therapy in the management of diarrhea
PharmacodynamicsDiphenoxylate, an antidiarrheal, is effective as adjunctive therapy in the management of diarrhea. Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood.
Mechanism of actionDiphenoxylate is an opiate receptor agonists that stimulate mu receptors in GI to decrease the peristalsis and constrict the sphincters. Diphenoxylate has a direct effect on circular smooth muscle of the bowel, that conceivably results in segmentation and prolongation of gastrointestinal transit time. The clinical antidiarrheal action of diphenoxylate may thus be a consequence of enhanced segmentation that allows increased contact of the intraluminal contents with the intestinal mucosa.
Related Articles
Absorption90%
Volume of distributionNot Available
Protein binding74-95%
Metabolism

Hepatic

Route of eliminationNot Available
Half life12-14 hours
ClearanceNot Available
ToxicityComa, dry skin and mucous membranes, enlarged pupils of the eyes, extremely high body temperature, flushing, involuntary eyeball movement, lower than normal muscle tone, pinpoint pupils, rapid heartbeat, restlessness, sluggishness, suppressed breathing
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Diphenoxylate Action PathwayDrug actionSMP00675
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9903
Blood Brain Barrier+0.9592
Caco-2 permeable+0.5316
P-glycoprotein substrateSubstrate0.7094
P-glycoprotein inhibitor IInhibitor0.7045
P-glycoprotein inhibitor IIInhibitor0.7845
Renal organic cation transporterInhibitor0.5967
CYP450 2C9 substrateNon-substrate0.8333
CYP450 2D6 substrateNon-substrate0.5667
CYP450 3A4 substrateNon-substrate0.5988
CYP450 1A2 substrateNon-inhibitor0.6827
CYP450 2C9 inhibitorInhibitor0.6701
CYP450 2D6 inhibitorInhibitor0.6461
CYP450 2C19 inhibitorInhibitor0.51
CYP450 3A4 inhibitorInhibitor0.5797
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.817
Ames testNon AMES toxic0.8482
CarcinogenicityNon-carcinogens0.839
BiodegradationNot ready biodegradable0.9805
Rat acute toxicity3.3423 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7969
hERG inhibition (predictor II)Inhibitor0.592
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Solutionoral
Tabletoral
Prices
Unit descriptionCostUnit
Lomotil 2.5-0.025 mg/5ml Liquid 60ml Bottle30.86USD bottle
Lomotil 2.5-0.025 mg tablet1.4USD tablet
Lomotil tablet1.12USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point220.5-222Janssen, P.A.J.; U.S.Patent 2,898,340; August 4,1959. Dryden, H.L. Jr. and Erickson, R.A.; U.S. Patent 4,086,234; April 25,1978; assigned to G.D.Searle & Co.
water solubility800 mg/L (at 25 °C)MERCK INDEX (1996)
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00146 mg/mLALOGPS
logP5.74ALOGPS
logP5.88ChemAxon
logS-5.5ALOGPS
pKa (Strongest Basic)8.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area53.33 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity146.76 m3·mol-1ChemAxon
Polarizability51.58 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-2390000000-0d133bb29f340639db02View in MoNA
References
Synthesis Reference

Janssen, P.A.J.; U.S.Patent 2,898,340; August 4,1959.
Dryden, H.L. Jr. and Erickson, R.A.; U.S. Patent 4,086,234; April 25,1978; assigned to
G.D.Searle & Co.

General ReferencesNot Available
External Links
ATC CodesA07DA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (49.7 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Diphenoxylate.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Diphenoxylate.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Diphenoxylate.
AcepromazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Diphenoxylate.
adipiplonThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Diphenoxylate.
AlimemazineAlimemazine may increase the hypotensive activities of Diphenoxylate.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diphenoxylate.
AlvimopanThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Diphenoxylate which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amobarbital.
AmoxapineDiphenoxylate may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Diphenoxylate.
AmperozideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Diphenoxylate.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Diphenoxylate.
AripiprazoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Asenapine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Diphenoxylate.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Diphenoxylate.
AzaperoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Azaperone.
AzelastineDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Diphenoxylate.
AzosemideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Diphenoxylate.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Diphenoxylate.
BenzocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Diphenoxylate.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benzyl alcohol.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Diphenoxylate.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
BrimonidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Diphenoxylate.
BuprenorphineBuprenorphine may decrease the analgesic activities of Diphenoxylate.
BuprenorphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Diphenoxylate.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenoxylate.
ButacaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Diphenoxylate.
ButorphanolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Diphenoxylate.
CarbinoxamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Diphenoxylate.
ChlormezanoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Diphenoxylate.
ChlorphentermineChlorphentermine may increase the analgesic activities of Diphenoxylate.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Diphenoxylate.
ChlorpromazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Diphenoxylate.
CitalopramDiphenoxylate may increase the serotonergic activities of Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with clomethiazole.
ClomipramineDiphenoxylate may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Diphenoxylate.
ClonazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenoxylate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Diphenoxylate.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Diphenoxylate.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Diphenoxylate.
ConivaptanThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Conivaptan.
CyclizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diphenoxylate.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Diphenoxylate.
CyclothiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diphenoxylate.
DapoxetineDiphenoxylate may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Diphenoxylate.
deramciclaneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Diphenoxylate.
DesmopressinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Diphenoxylate.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diphenoxylate.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Diphenoxylate.
DextromoramideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diphenoxylate.
DezocineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Diphenoxylate.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenoxylate.
DifenoxinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
DoxylamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Diphenoxylate.
DrospirenoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Diphenoxylate.
EcgonineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Efonidipine.
EluxadolineDiphenoxylate may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Diphenoxylate.
EntacaponeThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Eplerenone.
EscitalopramDiphenoxylate may increase the serotonergic activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diphenoxylate.
Etacrynic acidThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid.
EthanolDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Diphenoxylate.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diphenoxylate.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Diphenoxylate.
EthosuximideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Diphenoxylate.
EtoperidoneDiphenoxylate may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fencamfamine.
FenfluramineDiphenoxylate may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenoxylate.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Diphenoxylate.
FexofenadineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flunitrazepam.
FluoxetineDiphenoxylate may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Diphenoxylate.
FluphenazineFluphenazine may increase the hypotensive activities of Diphenoxylate.
FluphenazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenoxylate.
FluspirileneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluticasone Propionate.
FluvoxamineDiphenoxylate may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Diphenoxylate.
FosphenytoinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Diphenoxylate.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Diphenoxylate.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Diphenoxylate.
GuanfacineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Diphenoxylate.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Diphenoxylate.
HalothaneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Diphenoxylate.
HexobarbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Diphenoxylate.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Diphenoxylate.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenoxylate.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Diphenoxylate.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
HydroxyzineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Diphenoxylate.
IloperidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Imipramine.
IndalpineDiphenoxylate may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Indapamide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Diphenoxylate.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Diphenoxylate.
IsosorbideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketobemidone.
KW-3902The risk or severity of adverse effects can be increased when Diphenoxylate is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Diphenoxylate.
LevocabastineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levomethadyl Acetate.
LevomilnacipranDiphenoxylate may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenoxylate.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Diphenoxylate.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Diphenoxylate.
LithiumThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Diphenoxylate.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Diphenoxylate.
Lu AA21004Diphenoxylate may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Diphenoxylate.
LurasidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Diphenoxylate.
MeclizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Diphenoxylate.
MelperoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Diphenoxylate.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Diphenoxylate.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenoxylate.
MersalylThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Diphenoxylate.
MesoridazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Diphenoxylate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Diphenoxylate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Diphenoxylate.
MethapyrileneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Diphenoxylate.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Diphenoxylate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Diphenoxylate.
MethsuximideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Diphenoxylate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Diphenoxylate.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Diphenoxylate.
MetolazoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metolazone.
MetyrosineDiphenoxylate may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Diphenoxylate.
MilnacipranDiphenoxylate may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
MirtazapineDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Diphenoxylate.
MolindoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Diphenoxylate.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Diphenoxylate.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Diphenoxylate.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
NabiloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nabilone.
NalbuphineNalbuphine may decrease the analgesic activities of Diphenoxylate.
NalbuphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Naltrexone.
NitrazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Diphenoxylate.
OlanzapineDiphenoxylate may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diphenoxylate.
OlopatadineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Diphenoxylate.
OpiumThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Opium.
OrphenadrineDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Diphenoxylate.
OsanetantThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Diphenoxylate.
OxprenololThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Diphenoxylate.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Diphenoxylate.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diphenoxylate.
OxymorphoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Diphenoxylate.
PaliperidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Diphenoxylate.
ParaldehydeDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Diphenoxylate.
ParoxetineDiphenoxylate may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate.
PentazocinePentazocine may decrease the analgesic activities of Diphenoxylate.
PentazocineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Diphenoxylate.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Diphenoxylate.
PerampanelThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Diphenoxylate.
PerphenazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Diphenoxylate.
PhenobarbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Diphenoxylate.
PhenytoinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Diphenoxylate.
PipotiazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Diphenoxylate.
PiretanideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium Citrate.
PramipexoleDiphenoxylate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Diphenoxylate.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Diphenoxylate.
PrimidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Diphenoxylate.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Diphenoxylate.
ProchlorperazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Diphenoxylate.
PromazinePromazine may increase the hypotensive activities of Diphenoxylate.
PromazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Diphenoxylate.
PromethazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Diphenoxylate.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Diphenoxylate.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Diphenoxylate.
PropoxycaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Diphenoxylate is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Diphenoxylate.
RamelteonThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ramelteon.
RamosetronDiphenoxylate may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenoxylate.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Diphenoxylate.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Diphenoxylate.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Diphenoxylate.
RomifidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Romifidine.
RopiniroleDiphenoxylate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Diphenoxylate.
RotigotineDiphenoxylate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Diphenoxylate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Diphenoxylate.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Diphenoxylate.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diphenoxylate.
SertindoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sertindole.
SertralineDiphenoxylate may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Diphenoxylate.
SpironolactoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Diphenoxylate.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diphenoxylate.
SuvorexantThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Diphenoxylate.
TetrabenazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrodotoxin.
ThalidomideDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Diphenoxylate.
TheobromineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Diphenoxylate.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Diphenoxylate.
ThioridazineThioridazine may increase the hypotensive activities of Diphenoxylate.
ThioridazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tiagabine.
TicrynafenThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Diphenoxylate.
TizanidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Diphenoxylate.
TolvaptanThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Diphenoxylate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diphenoxylate.
TrazodoneDiphenoxylate may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Diphenoxylate.
TriamtereneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Diphenoxylate.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Diphenoxylate.
TrifluoperazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Diphenoxylate.
TriflupromazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Diphenoxylate.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Diphenoxylate.
TrimipramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Diphenoxylate.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Diphenoxylate.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Diphenoxylate.
UlaritideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Diphenoxylate.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Diphenoxylate.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Diphenoxylate.
VigabatrinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Vigabatrin.
VilazodoneDiphenoxylate may increase the serotonergic activities of Vilazodone.
VortioxetineDiphenoxylate may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Diphenoxylate.
XylazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Diphenoxylate.
ZiconotideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ziconotide.
ZimelidineDiphenoxylate may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Diphenoxylate.
ZolazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Diphenoxylate.
ZonisamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Baker DE: Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8. [PubMed:18192961 ]
  3. Corazziari E: Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol. 1999 Mar;13 Suppl A:71A-75A. [PubMed:10202212 ]
  4. Coupar IM: The peristaltic reflex in the rat ileum: evidence for functional mu- and delta-opiate receptors. J Pharm Pharmacol. 1995 Aug;47(8):643-6. [PubMed:8583364 ]
  5. De Luca A, Coupar IM: Difenoxin and loperamide: studies on possible mechanisms of intestinal antisecretory action. Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):231-7. [PubMed:8386327 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Coupar IM: The peristaltic reflex in the rat ileum: evidence for functional mu- and delta-opiate receptors. J Pharm Pharmacol. 1995 Aug;47(8):643-6. [PubMed:8583364 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23